Multiple Sclerosis Drug companies

Key Multiple Sclerosis Drug Market Players:

The international market is extremely unified, with the presence of notable key players, such as Biogen, Novartis, and Roche, collectively dominating with 65% of the market share through oral DMTs and monoclonal antibodies. These companies have readily implemented tactical initiatives, including transition to neuroprotection and approved administrative products. For instance, Biogen witnessed a sudden shift towards neuroprotection with USD 1.1 billion in research and development-based investment. Besides, Novartis’s Kesimpta gained 23% of the share with self-administered convenience, while Roche’s Ocrevus achieved 27% of the share through pediatric acceptances and expanded dosage, thus suitable for the market development.

Here is a list of key players operating in the global market:

Company Name	Country	Market Share (2024)
Roche	Switzerland	22.5%
Novartis	Switzerland	18.2%
Biogen	U.S.	15.4%
Merck KGaA	Germany	10.6%
Sanofi	France	9.1%
Teva Pharmaceutical	Israel	xx%
Bristol-Myers Squibb	U.S.	xx%
Pfizer	U.S.	xx%
Mylan (Viatris)	U.S.	xx%
Dr. Reddy’s Laboratories	India	xx%
Hetero Drugs	India	xx%
Biocon	India	xx%
Celltrion	South Korea	xx%
CSL Limited	Australia	xx%
Hikma Pharmaceuticals	UK	xx%

Below are the areas covered for each company in the market:

• Company Overview
• Business Strategy
• Key Product Offerings
• Financial Performance
• Key Performance Indicators
• Risk Analysis
• Recent Development
• Regional Presence
• SWOT Analysis